Opinion
Video
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
Author(s):
Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.
Related Videos
Related Content
